INKT
Price
$12.32
Change
+$0.07 (+0.57%)
Updated
Jun 23, 03:40 PM (EDT)
Capitalization
60.81M
50 days until earnings call
Intraday BUY SELL Signals
REVB
Price
$1.04
Change
-$0.01 (-0.95%)
Updated
Jun 23, 04:12 PM (EDT)
Capitalization
4.03M
45 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INKT vs REVB

INKT vs REVB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
INKT vs. REVB commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INKT is a Buy and REVB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2026
Stock price -- (INKT: $12.21 vs. REVB: $1.03)
Brand notoriety: INKT and REVB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INKT: 51% vs. REVB: 93%
Market capitalization -- INKT: $60.81M vs. REVB: $4.03M
INKT [@Biotechnology] is valued at $60.81M. REVB’s [@Biotechnology] market capitalization is $4.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INKT’s FA Score shows that 0 FA rating(s) are green whileREVB’s FA Score has 2 green FA rating(s).

  • INKT’s FA Score: 0 green, 5 red.
  • REVB’s FA Score: 2 green, 3 red.
According to our system of comparison, REVB is a better buy in the long-term than INKT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INKT’s TA Score shows that 5 TA indicator(s) are bullish while REVB’s TA Score has 4 bullish TA indicator(s).

  • INKT’s TA Score: 5 bullish, 4 bearish.
  • REVB’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both INKT and REVB are a good buy in the short-term.

Price Growth

INKT (@Biotechnology) experienced а -2.63% price change this week, while REVB (@Biotechnology) price change was +3.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

INKT is expected to report earnings on Aug 12, 2026.

REVB is expected to report earnings on Aug 07, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INKT($60.8M) has a higher market cap than REVB($4.03M). INKT YTD gains are higher at: 9.464 vs. REVB (-67.804). REVB has higher annual earnings (EBITDA): -10.04M vs. INKT (-12.67M). REVB has more cash in the bank: 14.1M vs. INKT (9.53M). REVB has less debt than INKT: REVB (759K) vs INKT (5.73M). INKT (0) and REVB (0) have equivalent revenues.
INKTREVBINKT / REVB
Capitalization60.8M4.03M1,510%
EBITDA-12.67M-10.04M126%
Gain YTD9.464-67.804-14%
P/E RatioN/A0.00-
Revenue00-
Total Cash9.53M14.1M68%
Total Debt5.73M759K754%
TECHNICAL ANALYSIS
Technical Analysis
INKTREVB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
59%
Advances
ODDS (%)
Bullish Trend 13 days ago
78%
Bullish Trend 15 days ago
76%
Declines
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
INKT
Daily Signal:
Gain/Loss:
REVB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RRX231.284.50
+1.98%
Regal Rexnord Corp
CBNK33.360.09
+0.27%
Capital Bancorp
XRTX2.06-0.03
-1.44%
XORTX Therapeutics Inc.
FUSB16.20-0.30
-1.81%
First US Bancshares
FSM9.05-0.21
-2.27%
Fortuna Mining Corp

INKT and

Correlation & Price change

A.I.dvisor indicates that over the last year, INKT has been closely correlated with REVB. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if INKT jumps, then REVB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INKT
1D Price
Change %
INKT100%
+0.54%
REVB - INKT
66%
Closely correlated
+5.10%
RAIN - INKT
43%
Loosely correlated
-9.71%
CYPH - INKT
42%
Loosely correlated
-2.19%
PHVS - INKT
40%
Loosely correlated
+0.61%
PTHS - INKT
37%
Loosely correlated
+0.97%
More

REVB and

Correlation & Price change

A.I.dvisor indicates that over the last year, REVB has been closely correlated with INKT. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if REVB jumps, then INKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REVB
1D Price
Change %
REVB100%
+5.10%
INKT - REVB
80%
Closely correlated
+0.54%
GNPX - REVB
48%
Loosely correlated
-6.69%
SABS - REVB
48%
Loosely correlated
-1.50%
TCRT - REVB
46%
Loosely correlated
+0.47%
OGEN - REVB
34%
Loosely correlated
+5.21%
More